Risk of Heparin-Induced Thrombocytopenia from Heparin-Bonded Vascular Prostheses

Annals of Vascular Surgery

Volumn 21, Issue 6, 2007, Pages 719-722

  Mureebe, Leila ^a   Graham, Joseph A ^b   Bush, Ruth L ^c   Silver, Donald ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; THROMBOCYTE ANTIBODY;

ARTICLE; ASSAY; AWARENESS; BLOOD DONOR; BLOOD SAMPLING; BLOOD VESSEL PROSTHESIS; CONTROLLED STUDY; EFFLUENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMERSION; LEACHING; PRIORITY JOURNAL; RISK; THEORETICAL STUDY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE POOR PLASMA;

ANTIBODIES; ANTICOAGULANTS; BLOOD PLATELETS; BLOOD VESSEL PROSTHESIS; HEPARIN; HUMANS; PLATELET AGGREGATION; POLYETHYLENE TEREPHTHALATES; PROSTHESIS DESIGN; RISK ASSESSMENT; THROMBOCYTOPENIA;

EID: 35549003250     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2007.07.016     Document Type: Article

References (26)

1. Iba T., Shin T., Sonoda T., et al. Stimulation of endothelial secretion of tissue-type plasminogen activator by repetitive stretch. J Surg Res 50 (1991) 457-460
2. Iba T., and Sumpio B.E. Tissue plasminogen activator expression in endothelial cells exposed to cyclic strain in vitro. Cell Transplant 1 (1992) 43-50
3. Lawrie G.M., Weilbacher D.E., and Henry P.D. Endothelium-dependent relaxation in human saphenous vein grafts. Effects of preparation and clinicopathologic correlations. J Thorac Cardiovasc Surg 100 (1990) 612-620
4. Pereira C.E., Albers M., Romiti M., et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg 44 (2006) 510-517
5. Begovac P.C., Thomson R.C., Fisher J.L., et al. Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg 25 (2003) 432-437
6. Gott V.L., Whiffen J.D., and Dutton R.C. Heparin Bonding on Colloidal Graphite Surfaces. Science vol. 142 (1963) 1297-1298
7. Serruys P.W., Emanuelsson H., van der Giessen W., et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 93 (1996) 412-422
8. Xue L., and Greisler H.P. Biomaterials in the development and future of vascular grafts. J Vasc Surg 37 (2003) 472-480
9. Esquivel C.O., Bjorck C.G., Bergentz S.E., et al. Reduced thrombogenic characteristics of expanded polytetrafluoroethylene and polyurethane arterial grafts after heparin bonding. Surgery 95 (1984) 102-107
10. Becquemin J.P., Riff Y., Kovarsky S., et al. Evaluation of a polyester collagen-coated heparin bonded vascular graft. J Cardiovasc Surg 38 (1997) 7-14
11. Almeida J.I., Liem T.K., and Silver D. Heparin-bonded grafts induce platelet aggregation in the presence of heparin-associated antiplatelet antibodies. J Vasc Surg 27 (1998) 896-901
12. Devine C., Hons B., and McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting: a multicenter trial. J Vasc Surg 33 (2001) 533-539
13. Devine C., and McCollum C. North West Femoro-Popliteal Trial. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg 40 (2004) 924-931
14. Laster J., and Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg 7 (1988) 667-672
15. Calaitges J.G., Liem T.K., Spadone D., et al. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg 29 (1999) 779-786
16. Almeida J.I., Coats R., Liem T.K., and Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 27 (1998) 309-316
17. Sanchez J., Elgue G., Riesenfeld J., and Olsson P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res 89 (1998) 41-50
18. Suh J.S., Aster R.H., and Visentin G.P. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 91 (1998) 916-922
19. Ao P.Y., Hawthorne W.J., Coombs R., and Fletcher J.P. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model. Int Angiol 18 (1999) 131-139
20. Ao P.Y., Hawthorne W.J., Taylor D.A., and Fletcher J.P. Optimal dose and duration of heparin for inhibition of intimal hyperplasia. Int Angiol 16 (1997) 94-100
21. Elsayed E., and Becker R.C. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 15 (2003) 11-18
22. Tyrrell D.J., Horne A.P., Holme K.R., et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46 (1999) 151-208
23. Clowes A.W., and Reidy M.A. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia-a review. J Vasc Surg 13 (1991) 885-891
24. Berk B.C., Gordon J.B., and Alexander R.W. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 17 6 Suppl B (1991) 111B-117B
25. Lambert A.W., Fox A.D., Williams D.J., et al. Experience with heparin-bonded collagen-coated grafts for infrainguinal bypass. Cardiovasc Surg 7 (1999) 491-494
26. Warkentin T.E. Heparin-induced thrombocytopenia and its treatment. J Thromb Thrombolysis 9 Suppl 1 (2000) S29-S35